Syncom Formulations Gains 3.47%: 3 Key Factors Driving the Week’s Momentum

09 February 2026: Technical Upgrade Spurs Initial Rally

Syncom Formulations began the week with a strong rally, closing at ₹14.34, up 5.83% from the previous close of ₹13.55. This surge followed MarketsMOJO’s upgrade of the stock’s rating from 'Sell' to 'Hold' on 09 Feb 2026, reflecting improved technical indicators and a cautiously optimistic view on the company’s recent financial performance. The upgrade was driven by a shift from bearish to mildly bearish technical trends, including easing downward momentum in MACD and Bollinger Bands, and a mildly bullish Dow Theory signal on the weekly timeframe.

Financially, the company reported positive quarterly results with an 8.29% growth in operating profit and a 72.46% increase in Profit After Tax (PAT) to ₹32.32 crores for the half-year. Despite long-term sales contraction, these short-term improvements supported the technical upgrade and attracted investor interest, as evidenced by the intraday high of ₹14.50 on the day.

10 February 2026: Mixed Technical Signals Temper Gains

The stock edged up slightly to ₹14.36 (+0.14%) on 10 Feb 2026, reflecting a cautious continuation of the prior day’s momentum. Technical indicators presented a nuanced picture: while the MACD remained bearish on weekly charts, it softened to mildly bearish monthly, and the RSI showed neutral momentum. Bollinger Bands and the KST indicator also suggested a mildly bearish stance, indicating potential resistance ahead.

Volume was moderate at 180,497 shares, and On-Balance Volume (OBV) failed to confirm a strong trend, signalling that buying interest was not yet robust enough to sustain a definitive uptrend. Dow Theory offered a mildly bullish weekly signal, but monthly readings remained inconclusive. The stock’s price remained well below its 52-week high of ₹23.46, highlighting the recovery phase rather than a full rebound.

12 February 2026: Strong Profit Growth Masks Revenue Concerns

On 12 Feb 2026, Syncom Formulations reported its Q3 FY26 results, revealing a robust profit growth that contrasted with underlying revenue challenges. The company’s operating profit growth of 8.29% and a 72.46% increase in PAT for the half-year underscored operational resilience and efficient capital utilisation, with ROCE at 22.06% and ROE at 16.6%. However, net sales growth remained subdued, reflecting ongoing long-term contraction trends.

This earnings report reinforced the cautious optimism reflected in the technical upgrade, but also highlighted the mixed financial trends that continue to temper enthusiasm. The stock closed marginally higher at ₹14.24 (+0.28%) on the day, supported by the positive earnings momentum despite broader market weakness.

13 February 2026: Week Ends on a Slight Decline Amid Market Weakness

The week concluded with Syncom Formulations closing at ₹14.02, down 1.54% on 13 Feb 2026, on heavy volume of 403,851 shares. This decline coincided with a broader market sell-off, as the Sensex fell 1.40% to 36,532.48. Despite the day’s negative price action, the stock’s weekly performance remained positive, outperforming the Sensex by 4.01% over the week.

The intraday volatility and volume spike suggest profit-taking or repositioning by investors following the week’s earlier gains and technical upgrade. The stock’s price remains above the week’s open of ₹13.55, indicating resilience amid mixed market conditions.

Key Takeaways

Positive Signals: The MarketsMOJO upgrade to Hold on 09 Feb 2026 marked a pivotal shift in technical sentiment, supported by improved momentum indicators and strong quarterly profit growth. The stock’s 3.47% weekly gain amid a declining Sensex highlights relative strength and resilience. Efficient capital utilisation, reflected in ROCE of 22.06% and ROE of 16.6%, alongside consistent profitability, underpin the cautious optimism.

Cautionary Notes: Despite recent gains, the stock remains below its 52-week high of ₹23.46, indicating room for recovery. Mixed technical signals, including bearish MACD and KST indicators and lack of volume confirmation, suggest that upward momentum is not yet firmly established. Long-term sales contraction and revenue concerns from the latest results temper enthusiasm. The absence of domestic mutual fund holdings also points to limited institutional confidence at current levels.

Conclusion

Syncom Formulations demonstrated a measured recovery during the week, driven by a technical upgrade and encouraging profit growth, which helped it outperform the Sensex by over 4%. However, the mixed technical landscape and underlying revenue challenges warrant a cautious stance. The stock’s recent price action suggests stabilisation rather than a definitive uptrend, with investors advised to monitor upcoming financial disclosures and technical developments closely. While the upgrade to Hold reflects improved fundamentals, the company’s long-term growth trajectory remains uncertain, underscoring the need for vigilance in the weeks ahead.

Unlock special upgrade rates for a limited period. Start Saving Now →